CTx, which brings together 11 different biotechnology R&D organisations, focuses on developing “high-risk” cancer drugs at a variety of research sites and institutions around the world.
The group said that it had opted to replace the traditional laboratory notebook approach with IDBS’ software following a series of very positive reports from member organisations that trialled the technology.
Glyn Williams, IDBS’ VP of marketing and project management, told in-PharmaTechnologist that: “CTx will use the software on their site to collect, analyse and manage all their proprietary data collected in the labs. The data is stored in [CTx’] own database[s], part of the E-workbook and ActivityBase products, located at their own sites.”
Williams added that CTx joins firms like UCB, Pfizer and China’s Pharmalegacy in selecting IDBS platforms for the management of drug development data.
The E-workbook is used as a general lab notebook for scientific data, drug metabolism and pharmacockinetics (DMPK), pharmacology, medicinal chemistry and safety studies. In contrast, ActivityBase is designed for high throughput screening, optimisation and data management.
In a press statement, Neil Kipling, founder and CEO of IDBS, said that: “IDBS’ investment in providing a complete solution to customers, rather than just software, has been recognised.
“Our continued investment in providing best-in-class products and our subsequent support for customers will help organizations such as CTx today and long into the future,” added Kipling.
Samantha Smith, operations manager for CTx, commented: “IDBS is obviously committed to the continuous improvement of their [software]. We receive quality and timely responses from the online support team, and interactions with IDBS technical support staff have been productive and helpful.”